表紙
市場調査レポート

次世代癌診断市場の予測 (2015-2025年):高度PCR技術・CTC検査・FISH検査・マイクロアレイ・NGS技術の主要開発企業の市場機会

Next-Generation Cancer Diagnostics Market Forecast 2015-2025: Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies

発行 Visiongain Ltd 商品コード 336178
出版日 ページ情報 英文 176 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=135.00円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
次世代癌診断市場の予測 (2015-2025年):高度PCR技術・CTC検査・FISH検査・マイクロアレイ・NGS技術の主要開発企業の市場機会 Next-Generation Cancer Diagnostics Market Forecast 2015-2025: Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies
出版日: 2015年07月27日 ページ情報: 英文 176 Pages
概要

2015年における世界の次世代癌診断の収益規模は16億ドルに達すると予測されており、2025年にかけても力強い収益成長が見込まれています。次世代スクリーニング (NGS) および循環腫瘍細胞 (CTC) の市場参入と新興国における需要の拡大が2025年にかけての売上の推進に貢献すると予測されています。

当レポートでは、世界の次世代癌診断市場について調査し、癌診断の手法および技術の種類と概要、市場全体の主要動向および成長見通し、検査/技術区分・地域/主要国別の動向と市場規模の推移と予測、主要企業のプロファイル、製品、取り組み、専門家へのインタビュー、SWOT分析などをまとめています。

第1章 エグゼクティブサマリー

第2章 イントロダクション:次世代癌診断

  • 癌とは
  • 癌診断の概要
    • スクリーニング
    • 診断
    • ステージング
  • 癌診断の手法
    • 身体検査
    • 画像技術
      • 超音波
      • CT
      • MRI
      • PET
    • 組織病理学的 ・細胞学的検査
    • 免疫組織化学 (IHC) 分析
    • 循環腫瘍細胞 (CTC) 分析
    • 分子診断・IVD
      • ポリメラーゼ連鎖反応 (PCR)
      • マルチプレックスPCR
      • リアルタイムPCR (RT-PCR or qPCR)
      • デジタルPCR (dPCR)
      • In Situハイブリダイゼーション (ISH)
      • マイクロアレイ
      • 次世代スクリーニング (NGS)
  • 遺伝性・後天性遺伝子突然変異検査
  • コンパニオン診断 (CDx)
  • 薬事未承認検査 (LDT:Laboratory Developed Test)
  • プレシジョンメディシン (Precision Medicine)
  • 政府による法規制
    • 米国
    • EU
  • 市場の定義

第3章 世界の次世代癌診断市場の予測

  • 世界の次世代癌診断市場:概要
  • 世界の次世代癌診断市場の予測
  • 部門別シェアの推移の予測
  • バイオマーカー・分子診断
    • 乳癌
    • 前立腺癌
    • 直腸癌
  • コンパニオン診断と2つの産業のコラボレーション
  • 承認済み検査に置き換えられるLDT
  • 診断検査の分散化
  • 次世代癌診断:成長推進因子・阻害因子

第4章 検査・技術区分別市場の予測

  • 先進PCR技術
    • 市場予測
    • 主要製品:リアルタイムPCR市場
    • 主要製品:デジタルPCR市場
    • PCRアッセイに置き換えられるパップテスト
    • 成長推進因子・阻害因子
  • In Situハイブリダイゼーション (ISH)
    • 市場予測
    • 主要製品:ISH癌診断市場
    • 乳癌のHER2検査
    • 成長推進因子・阻害因子
  • 循環腫瘍細胞 (CTC) 分析
    • 市場予測
    • 主要製品
    • Epic Sciences・LabCorp:アジア市場での拡張
    • CTCの超音波による分離
    • CTCクラスター:転移の原因に?
    • 成長推進因子・阻害因子
  • マイクロアレイ
    • 市場予測
    • 主要製品
    • 動向・開発状況
    • 成長推進因子・阻害因子
  • 次世代スクリーニング (NGS)
    • 市場予測
    • 主要製品
    • 動向・開発状況
    • 成長推進因子・阻害因子

第5章 主要国市場の予測

  • 世界の次世代癌診断市場の予測:地域別
  • 米国
  • EU5カ国
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • イタリア
  • 日本
  • 中国
  • インド
  • ブラジル
  • ロシア

第6章 主要企業

  • Roche Diagnostics
  • Abbott Laboratories
  • Qiagen
  • Thermo Fisher Scientific
  • Agilent Technologies
  • Hologic
  • Illumina
  • Myriad Genetics

第7章 定性分析・予測

  • SWOT分析

第8章 インタビュー

  • Keith Cannon氏 (Executive Vice President, Aviva Biosciences)
  • Nobuyoshi Katagiri博士 (Director, Diagnostics Development Department, Oncolys BioPharma)

第9章 総論

  • 世界の次世代癌診断市場
  • 次世代癌診断の将来

第10章 用語

図表

目次
Product Code: PHA0058

Next-generation cancer diagnostics - our new study reveals trends, R&D progress, and predicted revenues

Where is the next-generation cancer diagnostics market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2025, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 176-page report provides 87 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in the growing next-generation cancer diagnostics market.

Forecasts from 2015-2025 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including SWOT analysis), product profiles and commercial developments.
  • Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
    • Keith Cannon, Executive Vice President, Aviva Biosciences
    • Nobuyoshi Katagiri, Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you will find revenue forecasts to 2025 for the following submarkets:

  • Advanced PCR Techniques
  • In Situ Hybridisation
  • Circulating Tumour Cells
  • Microarray
  • Next-Generation Sequencing

image1

Our investigation discusses what stimulates and restrains business. You will understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?

You will discover individual revenue forecasts for leading national markets from 2015-2025:

  • US
  • Japan
  • EU5 (Germany, France, UK, Italy and Spain) as a group
  • China
  • India
  • Brazil
  • Russia
  • Rest of the World

image2

There will be growth in established developed markets and in developing countries. Our analyses show that China, in particular, will continue to achieve high revenue growth to 2025. Greater uptake of existing technology and products worldwide will also stimulate the industry and market.

Leading companies and the potential for market growth

Overall world revenue for next-generation cancer diagnostics will reach $1.6bn in 2015, our work calculates. We predict strong revenue growth through to 2025. Market entry of NGS and CTCs together with increasing demand from emerging markets will increase sales to 2025.

Our work identifies which organisations that hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. See visiongain's analysis of the leading companies developing the most innovative cancer diagnostic technologies, including these:

  • Roche Diagnostics
  • Abbott Laboratories
  • Qiagen
  • Thermo Fisher Scientific
  • Agilent Technologies
  • Hologic
  • Illumina
  • Myriad Genetics

image3

What issues will affect the next-generation cancer diagnostics industry?

Our new report discusses the issues and events affecting the next-generation cancer diagnostics market. You will find discussions, including qualitative analyses:

  • Savings that could be made with earlier screening and diagnosis
  • Increasing prevalence of cancer
  • Increasing awareness of molecular cancer diagnostics
  • Explosion in genomic and proteomic information
  • The trends in personalised medicine
  • The increasing adoption of companion diagnostics
  • The advent of innovative diagnostic methods

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Next-Generation Cancer Diagnostics Market Forecast 2015-2025: Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies report helps you

In summary, our 176-page report provides you with the following knowledge:

  • Revenue forecasts to 2025 for the world next-generation cancer diagnostics market and 5 leading segments - discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2025 for the leading national markets and regions - US, EU5, Japan, China, Brazil, Russia and Rest of the World
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market
  • View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the next-generation cancer diagnostics market and leading companies. You find data, trends and predictions.

Buy our report today Next-Generation Cancer Diagnostics Market Forecast 2015-2025: Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies. Avoid missing out - order our report now.

Table of Contents

1. Executive Summary

  • 1.1 Overview of Findings
  • 1.2 Structure of the Report
  • 1.3 Global Next-Generation Cancer Diagnostics Market Segmentation
  • 1.4 Why You Should Read This Report
  • 1.5 How This Report Delivers
  • 1.6 Key Questions Answered by This Analytical Report
  • 1.7 Who is This Report For?a
  • 1.8 Methodology
  • 1.9 Frequently Asked Questions (FAQ)
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2. Introduction to Next-Generation Cancer Diagnostics

  • 2.1 What Is Cancer?
  • 2.2 Cancer Diagnostics: An Overview
    • 2.2.1 Screening
    • 2.2.2 Diagnosis
    • 2.2.3 Staging
  • 2.3 Cancer Diagnosis Methods
    • 2.3.1 Physical Examination
    • 2.3.2 Imaging Techniques
      • 2.3.2.1 Ultrasound
      • 2.3.2.2 Computed Tomography (CT)
      • 2.3.2.3 Magnetic Resonance Imaging (MRI)
      • 2.3.2.4 Positron Emission Tomography (PET)
    • 2.3.3 Histopathological and Cytological Techniques
    • 2.3.4 Immunohistochemistry (IHC) Analysis
    • 2.3.5 Circulating Tumour Cell (CTC) Analysis
    • 2.3.6 Molecular Diagnostics and IVD
      • 2.3.6.1 Polymerase Chain Reaction (PCR)
      • 2.3.6.2 Multiplex PCR
      • 2.3.6.3 Real-Time PCR (RT-PCR or qPCR)
      • 2.3.6.4 Digital PCR (dPCR)
      • 2.3.6.5 In Situ Hybridisation (ISH)
      • 2.3.6.6 Microarray
      • 2.3.6.7 Next-Generation Sequencing (NGS)
  • 2.4 Tests for Inherited and Acquired Genetic Mutations
  • 2.5 Companion Diagnostics (CDx)
  • 2.6 Laboratory Developed Test (LDT)
  • 2.7 Precision Medicine
  • 2.8 Government Regulations
    • 2.8.1 The US Approval and Regulation System
    • 2.8.2 The EU Approval and Regulation System
  • 2.9 Market Definition

3. Next-Generation Cancer Diagnostics: World Market 2015-2025

  • 3.1 The Global Next-Generation Cancer Diagnostics Market: Overview
  • 3.2 The Global Next-Generation Cancer Diagnostics Market Forecast 2015-2025
  • 3.3 How Will Segmental Market Shares Change to 2025?
  • 3.4 Biomarkers and Molecular Diagnostics
    • 3.4.1 Biomarkers and Diagnostic Tests for Breast Cancer
    • 3.4.2 Biomarkers and Diagnostic Tests for Prostate Cancer
    • 3.4.3 Biomarkers and Diagnostic Tests for Colorectal Cancer
  • 3.5 Companion Diagnostics and Collaborations between Two Industries
  • 3.6 LDTs to be Replaced by Approved Tests
  • 3.7 Decentralisation of Diagnostic Tests
  • 3.8 Next-Generation Cancer Diagnostics: Drivers and Restraints 2015-2025

4. Next-Generation Cancer Diagnostics Submarkets 2015-2025

  • 4.1 Advanced PCR Techniques
    • 4.1.1 Advanced PCR Techniques Market Forecast 2015-2025
    • 4.1.2 Leading Products in the Real-Time PCR Market
      • 4.1.2.1 cobas 4800 System & Oncology Tests (Roche)
      • 4.1.2.2 QuantStudio Dx & 7500 Fast Dx (Thermo Fisher)
      • 4.1.2.3 Rotor-Gene Q & therascreen Tests (Qiagen)
      • 4.1.2.4 Oncotype DX (Genomic Health)
    • 4.1.3 Leading Products in the Digital PCR Market
    • 4.1.4 Pap Tests Being Replaced by PCR Assays
    • 4.1.5 Advanced PCR-Based Techniques: Drivers and Restraints 2015-2025
  • 4.2 In Situ Hybridisation (ISH)
    • 4.2.1 ISH Cancer Diagnostics Market Forecast 2015-2025
    • 4.2.2 Leading Products in the ISH Cancer Diagnostics Market
    • 4.2.3 HER2 Tests for Breast Cancer
    • 4.2.4 ISH Cancer Diagnostics: Drivers and Restraints 2015-2025
  • 4.3 Circulating Tumour Cells (CTCs) Analysis
    • 4.3.1 CTCs Analysis Market Forecast 2015-2025
    • 4.3.2 Leading Product in the CTCs Analysis Market
      • 4.3.2.1 CellSearch System (Janssen Diagnostics)
    • 4.3.3 Epic Sciences and LabCorp to Expand in Asia Markets
    • 4.3.4 CTCs Separation by Ultrasound
    • 4.3.5 CTC Clusters More Likely to Cause Metastasis?
    • 4.3.6 CTCs Analysis: Drivers and Restraints 2015-2025
  • 4.4 Microarray
    • 4.4.1 Microarray Cancer Diagnostics Market Forecast 2015-2025
    • 4.4.2 Leading Products in the Microarray Market
      • 4.4.2.1 OncoScan FFPE Assay Kit (Affymetrix)
      • 4.4.2.2 MammaPrint (Agendia)
    • 4.4.3 Microarray Cancer Diagnostics: Trends and Developments
      • 4.4.3.1 Array Comparative Genomic Hybridisation (Array CGH)
    • 4.4.4 Microarray Cancer Diagnostics: Drivers and Restraints 2015-2025
  • 4.5 Next-Generation Sequencing (NGS)
    • 4.5.1 NGS Cancer Diagnostics Market Forecast 2015-2025
    • 4.5.2 Leading Products in the NGS Market
      • 4.5.2.1 MiSeqDx (Illumina)
      • 4.5.2.2 Ion PGM Dx System (Thermo Fisher)
      • 4.5.2.3 GeneRead DNAseq Targeted Panels V2 (Qiagen)
    • 4.5.3 NGS Cancer Diagnostics: Trends and Developments
      • 4.5.3.1 Myriad Shifting from PCR to NGS Panel
      • 4.5.3.2 Competition in the NGS Market
      • 4.5.3.3 Bio-Rad to Commercialise NGS system for Clinical Use
      • 4.5.3.4 Qiagen Launched NGS Bioinformatics Platform
    • 4.5.4 NGS Cancer Diagnostics: Drivers and Restraints 2015-2025

5. Leading National Markets 2015-2025

  • 5.1 World Next-Generation Cancer Diagnostics Market: Regional Forecast 2015-2025
    • 5.1.1 How Will Regional Market Shares Change to 2025?
  • 5.2 US Next-Generation Cancer Diagnostics Market Forecast 2015-2025
    • 5.2.1 FDA Provides Guidance for Molecular Diagnostic Instruments with Combined Functions
    • 5.2.2 Obama Launched 'Precision Medicine Initiative'
    • 5.2.3 FDA and CMS to Regulate LDTs
  • 5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast 2015-2025
    • 5.3.1 Germany: Leading Market in the EU
    • 5.3.2 France: Reduction in Healthcare Spending
    • 5.3.3 UK: 100,000 Genomes Project
    • 5.3.4 Spain: Recovering from Financial Crisis
    • 5.3.5 Italy: Decreasing Reimbursement
  • 5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast 2015-2025
    • 5.4.1 Takeda Collaborated with NCC in Genomic Screening Project
    • 5.4.2 Qiagen Partnered Hitachi on PCR and NGS Technologies
    • 5.4.3 Increase Cancer Rates in Fukushima after Nuclear Disaster?
  • 5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast 2015-2025
    • 5.5.1 Illumina Entering the Chinese Market
    • 5.5.2 Epigenomics Colorectal Cancer Test Approved in China
    • 5.5.3 China Offered Free Screenings for Cervical and Breast Cancer
  • 5.6 Indian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
    • 5.6.1 Lack of Genetic Testing Regulation
    • 5.6.2 Cancer Genetics Launched NGS Cancer Panel in India
  • 5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
  • 5.8 Russian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
    • 5.8.1 IBM's Collaboration with Russian Companies to Advance Clinical Decision Making

6. Leading Companies in the Next-Generation Cancer Diagnostics Market 2015

  • 6.1 Roche Diagnostics
    • 6.1.1 Roche Diagnostics: Product Portfolio, 2015
    • 6.1.2 Roche Diagnostics: Diagnostics Outlook
    • 6.1.3 Cobas HPV Test Approved in the US in 2014
    • 6.1.4 Roche Diagnostics: Recent M&A Activity
    • 6.1.5 Roche Coming Back to the NGS Business?
  • 6.2 Abbott Laboratories
    • 6.2.1 Abbott: Next-Generation Cancer Diagnostics Product Portfolio 2015
    • 6.2.2 Abbott: Diagnostics Outlook
    • 6.2.3 Abbott Obtained Exclusive License for Bladder Cancer Biomarker FGFR3
  • 6.3 Qiagen
    • 6.3.1 Qiagen: Next-Generation Cancer Diagnostics Product Portfolio 2015
    • 6.3.1.1 Molecular Diagnostics Kits
    • 6.3.1.2 Real-Time PCR: Rotor-Gene Q
    • 6.3.1.3 Bioinformatics for NGS
    • 6.3.2 Qiagen: Market Outlook
    • 6.3.3 HalioDx Created from Qiagen Marseille
  • 6.4 Thermo Fisher Scientific
    • 6.4.1 Thermo Fisher Scientific: Business Segments
    • 6.4.2 Thermo Fisher: Next-Generation Cancer Diagnostics Product Portfolio 2015
      • 6.4.2.1 QuantStudio 3D (Digital PCR)
      • 6.4.2.2 In Situ Hybridisation
      • 6.4.2.3 Microarray Slides
      • 6.4.2.4 Next-Generation Sequencing
      • 6.4.2.5 Real-Time PCR for Oncology in Pipeline?
    • 6.4.3 Thermo Fisher: Life Sciences Outlook
    • 6.4.4 NGS Oncomine Focus Assay for Oncology Research
  • 6.5 Agilent Technologies
    • 6.5.1 Agilent: Next-Generation Cancer Diagnostics Product Portfolio 2015
      • 6.5.1.1 NGS Enrichment Platforms
      • 6.5.1.2 Cytogenetic Research and Microarrays
      • 6.5.1.3 Other Products
    • 6.5.2 Agilent: Life Sciences and Diagnostics Outlook
    • 6.5.3 Partnerships and Collaborations for Companion Diagnostics
  • 6.6 Hologic
    • 6.6.1 Hologic: Next-Generation Cancer Diagnostics Product Portfolio 2015
      • 6.6.1.1 Aptima HPV Assay and Cervista HPV Assay
      • 6.6.1.2 Progensa PCA3 Assay
    • 6.6.2 Hologic: Diagnostics Sales Outlook
  • 6.7 Illumina
    • 6.7.1 Illumina: Technology and Product Portfolio 2015
      • 6.7.1.1 Sequencing Technology
      • 6.7.1.2 BeadArray Microarray
      • 6.7.1.3 Consumables
      • 6.7.1.4 Services
    • 6.7.2 Illumina: Sales Outlook
    • 6.7.3 Illumina: Recent M&A Activity
    • 6.7.4 Joined Forces with UK Government for 100,000 Genomes Project
    • 6.7.5 Partnered with Merck Serono to Develop NGS Cancer Diagnostics
    • 6.7.6 Investing on Synthetic DNA Manufacturing Technology
  • 6.8 Myriad Genetics
    • 6.8.1 Myriad: Next-Generation Cancer Diagnostics Product Portfolio 2015
    • 6.8.2 Myriad: Sales Outlook
    • 6.8.3 New Landscape in the BRCA Diagnostic Market

7. Qualitative Analysis of the Next-Generation Cancer Diagnostics Market 2015-2025

  • 7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market
  • 7.2 Strengths
    • 7.2.1 Global Cancer Rates Set to Soar
    • 7.2.2 Increasing Awareness of Molecular Cancer Diagnostics
    • 7.2.3 The Trend in Precision Medicine
  • 7.3 Weaknesses
    • 7.3.1 Industry Facing Increasing Reimbursement Pressure
    • 7.3.2 Physicians' Reliance on Traditional Methods
  • 7.4 Opportunities
    • 7.4.1 Expanding Biomarkers and Cancer Test Menus
    • 7.4.2 Emerging Market to Provide Future Growth
    • 7.4.3 Companion Diagnostics on the Rise
  • 7.5 Threats
    • 7.5.1 Decreasing Healthcare Spending
    • 7.5.2 Gene Patenting Banned in the US?

8. Research Interviews

  • 8.1 Keith Cannon, Executive Vice President, Aviva Biosciences
    • 8.1.1 Aviva: From Research Laboratories to Clinical and Diagnostic Markets
    • 8.1.2 Ability to Distinguish CTCs is the Key
    • 8.1.3 RedSift(TM): Automated Enrichment of Nucleated Cells
    • 8.1.4 On Drivers and Restraints in the CTC Technologies Market
    • 8.1.5 On the Growth in Regional Markets
  • 8.2 Nobuyoshi Katagiri, Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma
    • 8.2.1 On Future Growth of Oncolys BioPharma
    • 8.2.2 CTCs is Changing the Market
    • 8.2.3 On Current Restraints in the Market
    • 8.2.4 ctDNA May Compete with Oncolys BioPharma's TelomeScan

9. Conclusions

  • 9.1 The World Next-Generation Cancer Diagnostics Market
    • 9.1.1 Current Leading Next-Generation Cancer Diagnostics Segments
    • 9.1.2 Notable Next-Generation Cancer Diagnostics Companies
    • 9.1.3 Leading Regional Markets
    • 9.1.4 World Next-Generation Cancer Diagnostics Market Forecast 2015-2025
  • 9.2 The Future of the Next-Generation Cancer Diagnostics Market

10. Glossary

List of Tables

  • Table 1.1 Leading National Next-Generation Cancer Diagnostics Market Forecast 2015-2025 ($m, AGR%, CAGR%)
  • Table 3.1 The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 3.2 Selected Biomarkers For Cancer Diagnostics
  • Table 3.3 FDA Approved Nucleic Acid Based Tests, 2015
  • Table 3.4 Selected Molecular Diagnostic Tests for Breast Cancer, 2015
  • Table 3.5 Selected Molecular Diagnostic Tests for Prostate Cancer, 2015
  • Table 3.6 Selected Molecular Diagnostics Test for Colorectal Cancer, 2015
  • Table 3.7 Companion Diagnostic Devices Approved by FDA, 2015
  • Table 4.1 Advanced PCR Techniques Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.2 ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.3 CTCs Analysis Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.4 Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 4.5 NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.1 World Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2014-2025
  • Table 5.2 US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.6 Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 5.8 Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
  • Table 6.1 Roche: Overview, 2015
  • Table 6.2 Roche Diagnostics: Key Instrument/Device Launches Planned for 2015
  • Table 6.3 Roche Diagnostics: Key Test Launches Planned for 2015
  • Table 6.4 Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
  • Table 6.5 Abbott Laboratories: Overview, 2015
  • Table 6.6 Abbott: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
  • Table 6.7 Qiagen: Overview, 2015
  • Table 6.8 Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
  • Table 6.9 Thermo Fisher: Overview, 2015
  • Table 6.10 Thermo Fisher: Life Sciences Solutions Segment Revenue ($m), AGR (%), 2012-2014
  • Table 6.11 Life Technologies: Revenue ($m), AGR (%), CAGR (%), 2008-2012
  • Table 6.12 Agilent: Overview, 2015
  • Table 6.13 Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
  • Table 6.14 Hologic: Overview, 2015
  • Table 6.15 Hologic: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
  • Table 6.16 Illumina: Overview, 2015
  • Table 6.17 Illumina: Sequencing Product Portfolio 2015
  • Table 6.18 Illumina: Microarray Product Portfolio 2015
  • Table 6.19 Illumina: Revenue ($m), AGR (%), CAGR (%), 2010-2014
  • Table 6.20 Myriad: Overview, 2015
  • Table 6.21 Myriad: Revenue ($m), AGR (%), CAGR (%), 2010-2014
  • Table 7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market, 2015-2025

List of Figures

  • Figure 1.1 New Cancer Cases and Deaths in More Developed and Less Developed Regions in 2012
  • Figure 1.2 Global Next-Generation Cancer Diagnostics Market Segmentation Overview 2015
  • Figure 3.1 Most Common Causes of Cancer Death, 2012
  • Figure 3.2 The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
  • Figure 3.3 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2014
  • Figure 3.4 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2019
  • Figure 3.5 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2025
  • Figure 3.6 Next-Generation Cancer Diagnostics: Market Drivers and Restraints 2015-2025
  • Figure 4.1 Advanced PCR Techniques Market: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.2 Advanced PCR-Based Techniques: Drivers and Restraints 2015-2025
  • Figure 4.3 ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.4 ISH Cancer Diagnostics: Drivers and Restraints 2015-2025
  • Figure 4.5 CTCs Analysis Market: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.6 CTCs Analysis: Drivers and Restraints 2015-2025
  • Figure 4.7 Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.8 Microarray Cancer Diagnostics: Drivers and Restraints 2015-2025
  • Figure 4.9 NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
  • Figure 4.10 NGS Cancer Diagnostics: Drivers and Restraints 2015-2025
  • Figure 5.1 New Cancer Cases and Deaths in More Developed and Less Developed Regions in 2012
  • Figure 5.2 World Next-Generation Cancer Diagnostics Market: Revenues ($m) by Region, 2014-2025
  • Figure 5.3 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2014
  • Figure 5.4 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2019
  • Figure 5.5 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2025
  • Figure 5.6 US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 5.7 EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 5.8 Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 5.9 Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 5.10 Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 5.11 Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 5.12 Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
  • Figure 6.1 Roche Diagnostics: Revenue Share (%) by Segment, 2014
  • Figure 6.2 Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), 2010-2014
  • Figure 6.3 Roche Diagnostics: Growth Rate (%) by Region, 2014
  • Figure 6.4 Abbott: Diagnostics Revenue ($m), AGR (%), 2010-2014
  • Figure 6.5 Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), 2010-2014
  • Figure 6.6 Life Technologies: Revenue ($m), AGR (%), 2008-2012
  • Figure 6.7 Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), 2010-2014
  • Figure 6.8 Hologic: Diagnostics Revenue ($m), AGR (%), 2010-2014
  • Figure 6.9 Illumina: Revenue Share (%) by Business Segment, 2014
  • Figure 6.10 Illumina: Revenue Share (%) by Geographic Area, 2014
  • Figure 6.11 Illumina: Revenue ($m), AGR (%), 2010-2014
  • Figure 6.12 Myriad: Revenue ($m), AGR (%), 2010-2014
  • Figure 6.13 Myriad: Revenue Share by Product (%), 2013
  • Figure 6.14 Myriad: Revenue Share by Product (%), 2014

Companies Listed

  • 454 Life Sciences
  • Abbott Laboratories
  • AbbVie
  • AbVitro
  • Advanced Cell Diagnostics
  • Advanced Liquid Logic
  • Affymetrix
  • Agendia
  • Agilent Technologies
  • Ambry
  • Amgen
  • Annoroad
  • Applied Biosystems
  • ARCH Venture Partners
  • AstraZeneca
  • Atossa Genetics
  • AvanSci
  • Aviva Biosciences
  • BD
  • Berry Genomics
  • BGI
  • Bina Technologies
  • Biobase
  • Biochain
  • BioFluidica
  • BioMarin Pharmaceutical
  • bioMérieux
  • Bio-Rad
  • BioServe India
  • BlueGnome
  • Bristol-Myers Squibb
  • Bruker
  • Cancer Genetics
  • Cepheid
  • CLC bio
  • CompanionDx
  • Counsyl
  • Crescendo Bioscience
  • CytoTrack
  • Dako
  • DakoCytomation
  • Danaher
  • DiagnoCure
  • DxS
  • Eli Lilly
  • Enzymatics
  • Epic Sciences
  • Epicentre Technologies
  • Epigenomics
  • Exact Sciences
  • Fidelity Management
  • Fluidigm
  • Fluxion
  • GeneDx
  • Genentech
  • Genia Technologies
  • Genomic Health
  • Gen-Probe
  • GnuBio
  • HalioDX
  • Hitachi High-Technologies
  • Hologic
  • Idaho Technology
  • IGEN International
  • Illumina
  • Ingenuity Systems
  • Insilico Medicine
  • Invitae
  • Invitrogen
  • Ipsogen
  • Iquum
  • Iris Molecular Diagnostics
  • Janssen Biotech
  • Janssen Diagnostics
  • LabCorp
  • Life Technologies
  • Luminex Corporation
  • Manostring Technologies
  • Merck
  • Miltenyi Biotec
  • Mylan
  • Myraqa
  • Myriad Genetics
  • NextBio
  • Oncolys BioPharma
  • Ono Pharmaceutical
  • Oxford Nanopore
  • Pacific Biosciences
  • Pathway Genomics
  • Pathway Pharmaceuticals
  • Pensabio
  • PerkinElmer
  • Pfizer
  • Prosigna
  • Qiagen
  • Qiagen Marseille
  • Quest Diagnostics
  • Quidel
  • RainDance Technologies
  • Rarecells
  • Roche Diagnostics
  • Sakura
  • Sanofi
  • ScreenCell
  • Siemens
  • Signature Diagnostics
  • Silicon Biosystems
  • SRI Biosciences
  • Stratos Genomics
  • Sysmex
  • Takeda
  • Thermo Fisher Scientific
  • Twist Bioscience
  • Ventana Medical Systems
  • Verinata Health
  • Vysis
  • Other Organisations Mentioned in This Report
  • Actionable Genome Consortium
  • Arizona State University
  • Carnegie Mellon University
  • First Oncology Research and Advisory Center
  • Genomics England
  • Institut Curie
  • MGH Cancer Center
  • Massachusetts Institute of Technology
  • National Cancer Center
  • Paris-Descartes University
  • Pennsylvania State University
Back to Top